In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....